0000000001089783

AUTHOR

Tk Eldin

showing 4 related works from this author

Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia.

2015

none 22 no Background: Few studies evaluated the clinical outcomes of Community Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP) and Health Care-Associated Pneumonia (HCAP) in relation to the adherence of antibiotic treatment to the guidelines of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) in hospitalized elderly people (65 years or older). Methods: Data were obtained from REPOSI, a prospective registry held in 87 Italian internal medicine and geriatric wards. Patients with a diagnosis of pneumonia (ICD-9 480-487) or prescribed with an antibiotic for pneumonia as indication were selected. The empirical antibiotic regimen was defined t…

MaleAntibiotic regimenGuidelines adherenceSettore MED/09 - Medicina InternaAntibioticsLogistic regressionElderlyCommunity-acquired pneumoniaAntibiotics80 and overElderly peopleAge FactorHospital MortalityAged 80 and overTreatment regimenMedicine (all)Age FactorsOptimal managementAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalization; Internal Medicine; Medicine (all)Anti-Bacterial AgentsHospitalizationTreatment OutcomePractice Guidelines as TopicFemaleGuideline AdherenceHumanmedicine.medical_specialtyLogistic Modelmedicine.drug_classSocio-culturaleantibiotic treatment; guidelines; pneumonia; elderly;Internal medicineRe-hospitalizationAnti-Bacterial AgentmedicineInternal MedicineHumanselderly pmeumonia antibiotics guidelines adherence mortality re-hospitalizationpmeumoniaMortalityIntensive care medicineAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalization; Internal MedicineAgedbusiness.industrySettore MED/09 - MEDICINA INTERNAAntibioticPneumoniamedicine.diseasePneumoniaAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalizationLogistic ModelsAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalizationbusiness
researchProduct

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

2016

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) acc…

MaleTORSADES-DE-POINTES INTERVAL PROLONGATION PATIENT CIPROFLOXACIN COHORT DEATH MULTIMORBIDITY AMIODARONE MORTALITY AIFA.Amiodarone030204 cardiovascular system & hematologyCIPROFLOXACINLogistic regressionAmiodaroneElectrocardiography0302 clinical medicineRisk FactorsTorsades de PointesAtrial Fibrillation80 and overPrevalencePharmacology (medical)030212 general & internal medicineAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalizationmedia_commonAged 80 and overTorsades de PointeAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Pharmacology (medical); Geriatrics and Gerontology; Medicine (all)Medicine (all)DEATHMiddle AgedPatient DischargeHospitalizationLong QT SyndromeCohortHospitalized Older PeopleFemalemedicine.drugHumanDrugmedicine.medical_specialtymedia_common.quotation_subjectMULTIMORBIDITYTorsades de pointesPATIENT03 medical and health sciencesPharmacotherapyInternal medicineINTERVAL PROLONGATIONmedicineHumansTORSADES-DE-POINTESCOHORTMedical prescriptionAIFAAgedbusiness.industryMORTALITYRisk FactorSettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseQT-Prolonging DrugAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Geriatrics and Gerontology; Pharmacology (medical)Physical therapyGeriatrics and Gerontologybusiness
researchProduct

Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI

2014

none 10 no The dramatic demographic changes that are occurring in the third millennium are modifying the mission of generalist professionals such as primary care physicians and internists. Multiple chronic diseases and the related prescription of multiple medications are becoming typical problems and present many challenges. Unfortunately, the available evidence regarding the efficacy of medications has been generated by clinical trials involving patients completely different from those currently admitted to internal medicine: much younger, affected by a single disease and managed in a highly controlled research environment. Because only registries can provide information on drug effectiven…

Adverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged; 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies; Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineMalemedicine.medical_specialtyAgingmedia_common.quotation_subjectDrug prescriptionMEDLINEAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineDiseaseComorbidityAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; PolypharmacyelderlyAdverse drug effectsPromotion (rank)MedicalmedicineAdverse drug effect80 and overInternal MedicineHumansRegistriesMedical prescriptionmedia_commonAgedGeriatricsPolypharmacyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Emergency Medicine; Internal MedicineMultimorbidity Polypharmacy Aging Drug prescription Multidimensional evaluation Adverse drug effectsMultidimensional evaluationbusiness.industrySettore MED/09 - MEDICINA INTERNAMultimorbiditymedicine.diseaseComorbidityelderly multimorbidity polypharmacyClinical trialItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineFemaleMedical emergencyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicinebusinessSocietiesmultimorbidity; polypharmacy; aging; drug prescription; multidimensional evaluation; adverse drug effectsMultimorbidity; Polypharmacy; Aging; Drug prescription; Multidimensional evaluation
researchProduct

Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistr…

2017

BACKGROUND: Older patients are prone to multimorbidity and polypharmacy, with an inherent risk of adverse events and drug interactions. To the best of our knowledge, available information on the appropriateness of lipid-lowering treatment is extremely limited. AIM: The aim of the present study was to quantify and characterize lipid-lowering drug use in a population of complex in-hospital older patients. METHODS: We analyzed data from 87 units of internal medicine or geriatric medicine in the REPOSI (Registro Politerapie della Società Italiana di Medicina Interna) study, with reference to the 2010 and 2012 patient cohorts. Lipid-lowering drug use was closely correlated with the clinical prof…

Malemedicine.medical_specialtyLogistic ModelLipid-Lowering AgentsPopulationSocio-culturaleOlder Hospitalized Patients030204 cardiovascular system & hematologyGeriatrics and Gerontology; Pharmacology (medical)03 medical and health sciences0302 clinical medicineInternal medicine80 and overPrevalencemedicineHumansPharmacology (medical)030212 general & internal medicineMedical prescriptionIntensive care medicineOmega 3 fatty acideducationAdverse effectAgedHypolipidemic AgentsAged 80 and overPolypharmacyGeriatricseducation.field_of_studyHypolipidemic Agentbusiness.industryGeriatrics and Gerontology Pharmacology (medical)HospitalizationLogistic ModelsCohortPolypharmacyAged; Aged 80 and over; Female; Hospitalization; Humans; Hypolipidemic Agents; Logistic Models; Male; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)FemaleGeriatrics and GerontologybusinessAged; Aged 80 and over; Female; Hospitalization; Humans; Hypolipidemic Agents; Logistic Models; Male; Polypharmacy; PrevalenceHumanCohort study
researchProduct